Published: Fri, August 11, 2017
Economy | By Annette Adams

Astrazeneca PLC (NYSE:AZN) Experiences Heavier than Average Trading Volume

Astrazeneca PLC (NYSE:AZN) Experiences Heavier than Average Trading Volume

Cowen and Company reaffirmed a "hold" rating and issued a $34.00 price objective on shares of Astrazeneca PLC in a research note on Friday, July 28th.

AZN has been the topic of several other research reports. Pareto Securities upgraded shares of Astrazeneca PLC from a sell rating to a hold rating in a research report on Tuesday, August 1st. Citigroup Inc. raised their target price on shares of Tp Icap Plc from GBX 435 ($5.66) to GBX 485 ($6.32) and gave the company a "neutral" rating in a research note on Tuesday, July 11th. Barclays PLC restated an overweight rating on shares of Astrazeneca PLC in a research report on Thursday, July 13th. As per Friday, April 29, the company rating was downgraded by Maxim Group. (NYSE:VZ), 6 have Buy rating, 0 Sell and 18 Hold. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal. The stock now has a consensus rating of Hold and a consensus price target of GBX 269.67 ($3.51). The stock's 50 day moving average price is GBX 890.27 and its 200-day moving average price is GBX 880.92. According to these analysts, the Low Revenue Estimate for AstraZeneca PLC is 5.1 Billion and the High Revenue Estimate is 5.92 Billion. Many investors may be looking too closely at stocks that have been on the rise, and they might not be checking on the underlying fundamental data. This is an increase of approximately 1,510% compared to the typical volume of 513 put options. The stock of Card Factory PLC (LON:CARD) earned "Buy" rating by Peel Hunt on Tuesday, September 27. The Lower end of the earnings estimate is $0.49, while the higher end of the earnings estimate is $0.54. The Return on Equity (ROE) value stands at 28.4%. On September 14 the stock rating was downgraded from " to "Neutral" by analysts at Exane BNP Paribas. AZN generated revenue of $5.51 Billion in the same quarter, one year ago. The firm's revenue was down 9.9% compared to the same quarter previous year.

While looking at the Stock's Performance, AstraZeneca PLC now shows a Weekly Performance of -2.84%, where Monthly Performance is -11.34%, Quarterly performance is -5.06%, 6 Months performance is 2.97% and yearly performance percentage is -13.68%. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/08/10/synthomer-plc-lonsynt-price-target-raised-to-gbx-500-at-numis-securities-ltd.html. If you are accessing this piece on another publication, it was stolen and republished in violation of global copyright and trademark legislation. Deutsche Bank maintained CVS Health Corp (NYSE:CVS) on Wednesday, July 22 with "Hold" rating. As per Friday, August 4, the company rating was maintained by Pivotal Research. The ex-dividend date of this dividend is Thursday, October 5th. This represents a dividend yield of 1.67%. Astrazeneca PLC's dividend payout ratio is now 44.92%.

Here are a few other firms who have also updated their positions. Macquarie Group Ltd. boosted its stake in Astrazeneca PLC by 13.1% in the fourth quarter. About shares traded. Mistras Group Inc (NYSE:MG) has declined 10.21% since August 10, 2016 and is downtrending. The value of the investment in Astrazeneca PLC decreased from $1,218,000 to $220,000 a change of 81.9% since the last quarter. Teachers Advisors LLC now owns 787,179 shares of the company's stock valued at $21,506,000 after buying an additional 30,104 shares during the period. 1,778,820 stocks of the shares were exchanged. Finally, Creative Planning boosted its stake in Astrazeneca PLC by 9.8% in the first quarter. The stock of Viacom, Inc.

Viking Global Investors Lp decreased Astrazeneca Plc (AZN) stake by 31.53% reported in 2016Q4 SEC filing. The Stock now has a Weekly Volatility of 1.10% and Monthly Volatility of 1.79%.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold.

Like this: